Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-GUT
NCT05965440Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dapagliflozin in chronic kidney disease (CKD), sponsored by Hospices Civils de Lyon. Primary endpoint: Alpha diversity and beta diversity size of the intestinal microbiota at 12 weeks. Started Nov 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05965440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965440.